Semax vs Selank: Nootropic Peptide Comparison (2026)

Semax and Selank are both Russian-developed research peptides studied for brain effects, but they target different systems. Semax (an ACTH(4–10) analog) is studied mainly for cognition and neuroprotection via BDNF upregulation, while Selank (a tuftsin analog) is studied mainly as an anxiolytic acting on GABAergic and serotonergic systems. Neither is FDA-approved.

Semax vs Selank at a glance

What is the core difference between Semax and Selank?

Semax and Selank are both synthetic heptapeptides developed in Russia from naturally occurring peptide fragments, but they were designed for different jobs.

Semax is an analog of a fragment of adrenocorticotropic hormone, ACTH(4–10), modified with a C-terminal Pro-Gly-Pro tail to resist enzymatic breakdown. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered in Russia as a nootropic and neuroprotective drug for ischemic stroke and cognitive impairment. Western evidence is largely preclinical, and most human data come from Russian-language clinical publications.

Selank is an analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), similarly extended with a Pro-Gly-Pro tail to improve metabolic stability and duration of action (Volkova et al., 2016, Front Pharmacol). It was developed by the same institute as an anxiolytic ("anti-anxiety") peptide and is registered as a drug in Russia for anxiety disorders.

The practical distinction researchers draw: Semax is studied primarily as a cognitive/neuroprotective agent (focus, mental fatigue, stroke recovery), while Selank is studied primarily as an anxiolytic agent (anxiety, stress, asthenia) that may also offer modest cognitive support. They are related tools aimed at different parts of the same problem. Neither is approved by the FDA, and human trial data for both remain limited and concentrated in Russia.

For a deeper single-compound breakdown, see our Semax protocol guide and Selank protocol guide.

How does Semax work?

Semax's best-documented mechanism is rapid upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, which drive neuronal survival, synaptic plasticity, and long-term potentiation.

In a controlled rodent study, a single dose of Semax (50 mcg/kg) produced a maximal 1.4-fold increase in BDNF protein and a 1.6-fold increase in TrkB tyrosine phosphorylation, alongside a roughly 3-fold rise in exon-III BDNF mRNA and 2-fold rise in TrkB mRNA in the rat hippocampus (Dolotov et al., 2006, Brain Res, PMID 16996037). A companion study found Semax binds specifically in the rat basal forebrain and raises BDNF protein there (Dolotov et al., 2006, J Neurochem, DOI 10.1111/j.1471-4159.2006.03658.x).

Beyond neurotrophins, Semax modulates monoamine systems. In rodents it exerted a positive modulatory effect on the striatal serotonergic system and amplified dopamine release and locomotor activity when given before amphetamine, though Semax alone did not change baseline dopamine (Eremin et al., 2005, Neurochem Res, PMID 16362768).

Semax has also been studied as a neuroprotectant. In a rat model of cerebral ischemia–reperfusion (transient middle cerebral artery occlusion), Semax shifted protein-expression markers toward survival — downregulating phosphorylated JNK and the inflammatory markers MMP-9 and c-Fos while upregulating phosphorylated CREB (Sudarkina et al., 2021, Int J Mol Sci, PMID 34201112, DOI 10.3390/ijms22126179). These are animal-model and molecular findings; they describe what Semax may support, not proven human treatment effects. Consult your healthcare provider before drawing conclusions about your own use.

How does Selank work?

Selank's best-documented mechanism is anxiolytic modulation of the GABAergic and serotonergic systems, without binding the benzodiazepine site directly and without the dependence profile of benzodiazepines.

Rather than acting like a benzodiazepine at the receptor, Selank appears to influence the specific binding of GABA to GABA-A receptors — an allosteric or affinity-shifting effect — and to modulate the genes involved in GABAergic neurotransmission (Volkova et al., 2016, Front Pharmacol, PMID 26924987, DOI 10.3389/fphar.2016.00031). A follow-up cell study found Selank alone did not change GABA-A subunit mRNA levels but altered the gene-expression response to GABA, consistent with an interaction at the receptor rather than direct transcriptional control (Filatova et al., 2017, Front Pharmacol, DOI 10.3389/fphar.2017.00089).

Selank also engages the endogenous opioid system. In patients with generalized anxiety disorder, shortened enkephalin half-life correlated with anxiety severity, and Selank treatment lengthened enkephalin half-life as anxiety fell (Zozulia et al., 2008, Zh Nevrol Psikhiatr Im S S Korsakova, PMID 18454096). It carries immunomodulatory activity too, consistent with its tuftsin origin, shifting Th1/Th2 cytokine balance and IL-6 expression in patients with anxiety-asthenic disorders (Uchakina et al., 2008, Zh Nevrol Psikhiatr Im S S Korsakova, PMID 18577961).

In an animal stress model, intranasal Selank (300 mcg/kg daily for 14 days) combined with diazepam reduced anxiety under chronic mild stress more effectively than either agent alone (Kasian et al., 2017, Behav Neurol, PMID, DOI 10.1155/2017/5091027). As with Semax, these are preclinical and small-clinical findings describing what Selank may support. Consult your healthcare provider before considering any protocol.

When should you consider Semax vs Selank?

There is no head-to-head human trial directly comparing Semax and Selank for the same endpoint, so any "which is better" framing is an indirect inference from each compound's separate research base — not a proven comparison. The mapping below reflects how each peptide is studied, not a treatment recommendation.

Importantly, both peptides remain investigational in the US. The "more-studied" label means more published research exists, not that the peptide is safe or effective for you. Individual response varies, and self-experimentation with unapproved compounds carries unknown risks. Consult your healthcare provider before starting any peptide protocol.

What dosing do research protocols cite for Semax and Selank?

The figures below describe doses used in published research and commonly cited in research-protocol conventions — they are reported for education, not as instructions. Both peptides are most often studied via intranasal administration because it provides direct nose-to-brain access and bypasses rapid degradation in blood.

Semax (research-cited ranges):

• Russia registers two intranasal concentrations: 0.1% (cognitive/asthenic indications) and 1% (acute ischemic stroke, optic nerve atrophy).
• Cognitive research protocols commonly cite roughly 250–600 mcg/day intranasal, often split across the day, in short runs.
• One human-physiology study reported attention and short-term-memory effects across a 250–1000 mcg/kg range [VERIFY: exact dose-response and sample size]; an fMRI pilot used a 1% intranasal solution at a total dose near 1.2 mg [VERIFY: n and effect size].

Selank (research-cited ranges):

• Research protocols commonly cite roughly 250–900 mcg/day intranasal.
• The 14-day rat stress study used 300 mcg/kg/day intranasal (Kasian et al., 2017, Behav Neurol); human clinical trials used a registered intranasal formulation over ~14-day courses (Zozulia et al., 2008).

Selank's plasma half-life is short — on the order of a few minutes — yet a single intranasal dose produces downstream CNS effects lasting hours, which is why daily dosing is studied despite rapid clearance [VERIFY: precise human pharmacokinetics]. Neither compound has an FDA-established human dose, and "research protocols commonly cite" is not a personalized recommendation. Dosing should be personalized with a provider. Consult your healthcare provider before starting any peptide protocol.

How do Semax and Selank compare on safety and side effects?

Both peptides are generally described in the available literature as well tolerated at studied doses, but the human safety database for each is small, short-term, and concentrated in Russia — so the absence of reported serious effects is not the same as proven long-term safety.

Two cautions stand out. First, Selank potentiated diazepam's anxiolytic effect in animals, so combining it with benzodiazepines or other CNS depressants is theoretically risky and unstudied in humans (Kasian et al., 2017). Second, Semax modulates dopamine and serotonin signaling (Eremin et al., 2005), which raises theoretical interaction concerns with antidepressants, stimulants, or other serotonergic/dopaminergic agents. Product purity is a separate, real-world risk: research-grade peptides are not manufactured to pharmaceutical standards, and contamination or mislabeling is possible. Consult your healthcare provider before starting any peptide protocol, and disclose all medications you take.

What do Semax and Selank cost, and can you legally get them in NYC?

Neither Semax nor Selank is FDA-approved, and neither is sold by Peptides.NYC. As of June 2026, both are most commonly marketed in the US as "research chemicals," typically as lyophilized powder or pre-mixed intranasal solutions, with prices that vary widely by vendor, concentration, and purity. Pharmaceutical-grade product (as registered in Russia) is generally not available through normal US channels. Because pricing and sourcing change quickly, we do not publish specific dollar figures here [VERIFY: current NYC/online price-per-mg ranges].

The regulatory picture is the most important — and most current — piece:

• Selank acetate (TP-7) was removed from the FDA's 503A Category 2 interim bulk-substances list after the nominators withdrew the nominations, effective September 27, 2024 (alongside AOD-9604, CJC-1295, ipamorelin acetate, and thymosin alpha-1) — Semax was not part of this action. Removal from Category 2 does not grant Category 1 status or make compounding automatically permissible.
• On April 15, 2026, the FDA announced removal of 12 additional peptides from Category 2 — including Semax — following further nomination withdrawals, effective April 22, 2026, and scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting (Docket No. FDA-2025-N-6895).
• The PCAC meets July 23–24, 2026 to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon — should be added to the Section 503A Bulk Drug Substances List. On July 24, 2026, the committee is slated to discuss Semax (free base) and Semax acetate (FDA Advisory Committee Calendar, July 23–24, 2026).
• Selank is not on the July 2026 PCAC agenda. Its path back into legal compounding is therefore less clear than Semax's at this time.
• PCAC recommendations are advisory only; the FDA must complete formal rulemaking before any reclassification takes effect, even after a favorable vote.

No peptide discussed here is DEA-scheduled. Legal status varies by jurisdiction, and the situation is actively evolving — see our peptide legal status tracker for updates. Legal status varies by jurisdiction; consult a lawyer for binding advice, and consult your healthcare provider before any use.

Can you stack Semax and Selank together?

Many research and biohacking sources describe Semax and Selank as complementary because they act on largely different systems — Semax on BDNF/monoamine pathways for cognition, Selank on GABA/serotonin pathways for anxiety — so they are often discussed as a "calm focus" pairing rather than a redundant one. However, there is no human clinical trial validating the combination for safety or efficacy, so any stacking is unstudied and experimental.

The theoretical rationale is mechanistic non-overlap: Semax may support attention and neurotrophic signaling while Selank may support stress tolerance, and neither is reported to cause sedation. The theoretical risks are also real: combining two monoamine- and GABA-active peptides could produce additive or unpredictable neurochemical effects, and Selank's demonstrated potentiation of diazepam (Kasian et al., 2017) is a reminder that Selank can amplify other CNS agents. Because both are unapproved and unstandardized, stacking compounds the uncertainty around purity, dosing, and interactions.

This is an area where "common practice online" is not evidence. If you are considering any combination, that decision belongs with a licensed provider who knows your full history and medication list. Consult your healthcare provider before starting any peptide protocol. For related pairings, see our nootropic peptides hub.

Frequently asked questions

Q: What is the main difference between Semax and Selank? A: Semax is an ACTH(4–10) analog studied mainly for cognition and neuroprotection, working largely by upregulating BDNF and its TrkB receptor (Dolotov et al., 2006). Selank is a tuftsin analog studied mainly as an anxiolytic, working through GABA-A modulation and serotonin turnover without the dependence profile of benzodiazepines (Volkova et al., 2016; Zozulia et al., 2008). In short: Semax leans cognitive, Selank leans calming. Both are Russian-developed research peptides, neither is FDA-approved, and human data are limited. Consult your healthcare provider before considering either.

Q: Is Semax or Selank better for anxiety? A: Selank is the more-studied option for anxiety. In a controlled clinical trial, Selank produced anxiolytic effects comparable to the benzodiazepine medazepam on Hamilton and Zung scales, while also showing anti-asthenic and mild psychostimulant effects the benzodiazepine lacked, and without sedation or dependence (Zozulia et al., 2008). Semax is studied for cognition and neuroprotection, not primarily anxiety. "More-studied" does not mean proven safe or effective for you. Consult your healthcare provider before using any peptide for anxiety.

Q: Can you take Semax and Selank at the same time? A: Some sources describe them as complementary because they act on different systems — Semax on cognition-related BDNF and monoamine pathways, Selank on anxiety-related GABA and serotonin pathways. However, no human trial has tested the combination for safety or efficacy, so any stacking is experimental. Selank can potentiate other CNS agents (it amplified diazepam in animals; Kasian et al., 2017), which is one reason combinations warrant caution. Consult your healthcare provider before combining any peptides.

Q: Are Semax and Selank FDA-approved or legal in the US? A: Neither is FDA-approved. Selank acetate was removed from the FDA's 503A Category 2 interim compounding list effective September 27, 2024, after nomination withdrawals; Semax was removed later, in the 12-peptide action effective April 22, 2026. As of June 2026, Semax is on the agenda for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, while Selank is not. PCAC recommendations are advisory only, and the FDA must complete formal rulemaking before any reclassification. No peptide here is DEA-scheduled. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: How are Semax and Selank usually administered? A: Both are most often studied intranasally, because the nasal route gives direct nose-to-brain access and bypasses rapid breakdown in blood. Russia registers Semax as 0.1% and 1% intranasal solutions; Selank is similarly used intranasally in trials and research protocols. Some users also report subcutaneous injection, but the published human data center on intranasal delivery. There is no FDA-established human dose for either. Consult your healthcare provider before starting any peptide protocol.

Q: How long do Semax and Selank take to work? A: In animal and small clinical studies, effects on neurochemistry can appear within hours — Semax raised hippocampal BDNF and TrkB activity after a single dose (Dolotov et al., 2006), and Selank's downstream CNS effects outlast its few-minute plasma half-life. Subjective cognitive or anxiety effects in human trials were typically assessed over multi-week courses (Zozulia et al., 2008). Timelines and individual response vary, and human evidence is limited. Discuss realistic expectations with a healthcare provider.

Q: Do Semax and Selank have side effects? A: Both are described as generally well tolerated at studied doses, with no characteristic sedation or dependence reported for Selank (Zozulia et al., 2008). Mild effects such as nasal irritation are possible with intranasal use. The human safety database for each is small and short-term, so long-term safety is not established, and research-grade product carries purity risks. Selank may potentiate sedatives, and Semax modulates monoamines, raising theoretical interaction concerns. Consult your healthcare provider and disclose all medications before use.

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037. https://pubmed.ncbi.nlm.nih.gov/16996037/
2. Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. DOI: 10.1111/j.1471-4159.2006.03658.x. https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.03658.x
3. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768. https://pubmed.ncbi.nlm.nih.gov/16362768/
4. Sudarkina OY, Filippenkov IB, Stavchansky VV, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021;22(12):6179. PMID: 34201112. DOI: 10.3390/ijms22126179. https://pmc.ncbi.nlm.nih.gov/articles/PMC8226508/
5. Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26924987. DOI: 10.3389/fphar.2016.00031. https://pubmed.ncbi.nlm.nih.gov/26924987/
6. Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89. DOI: 10.3389/fphar.2017.00089. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00089/full
7. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behav Neurol. 2017;2017:5091027. DOI: 10.1155/2017/5091027. https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/
8. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic drug Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. https://pubmed.ncbi.nlm.nih.gov/18454096/
9. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. PMID: 18577961. https://pubmed.ncbi.nlm.nih.gov/18577961/
10. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket No. FDA-2025-N-6895. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
11. U.S. Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A (503A bulk drug substances list / Category status). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act